Posted on

Mikhail Blagosklonny life and career as a research scientist.

For many years now scientist from all over the world have been trying to decipher the aging process in a human being and how it can be stopped or made to slow down. Many scientists have therefore rededicated their study and time to the new science of aging, and as a result, significant advancements have been made. One such scientist who for many years now has been carrying out endless experiments on new ways of solving or indeed stopping the aging process is Mikhail Blagosklonny.

Mikhail Blagosklonny is a renowned scientist who is well known for his research work when it comes to both the study of cancer and the aging process in human beings. Aside from that, Blagosklonny doubles up as a professor and a philanthropist who always wants to help those that are less fortunate in the society. It is this nature of caring for others that drive Michael to strive to find a cure or come up with new and improved treatment regiments for cancer at a lower price affordable to everyone and more information click here.

Blagosklonny’s educational background is one that exudes exceptional brilliance having attended some of the top institutions attaining a medical degree and later on pursuing his Ph. D. in the field of cardiology and experimental medicine. In the year 2009, he became a senior scientist at a research center called Ordway Research Institute but begun his professorship back in 2002 at New York Medical College and resume him.

In his quest as a researcher, Mikhail Blagoskonny is profoundly interested in the interrelation between cancer and aging in people. Research conducted previously revealed that cancer tends to occur in older people who are, mostly above a certain age. His research projects have significantly contributed a significant amount of knowledge to the field of oncology.

The research carried out by Blagoskonny about finding a cure for cancer and aging process majorly relies on rapamycin. In his quest, the observation made earlier associating the development of cancer and aging was solvable by being able to administer rapamycin safely. Rapamycin itself is an agent that slows down aging and in turn reducing the rate of people contracting cancer. This school of thought indeed had grounds of support from numerous studies that had been done on rats showing that this is indeed practical.

The ability of rapamycin delaying the aging process and cancer development itself can subsequently be reduced in people who use rapamycin. However, there is catch to the effectiveness of rapamycin when the ultimate goal is limiting the development of cancer. This is because for rapamycin to function effectively, its administration should occur before cancer develops in a person. Its administration after cancer has started developing would be futile since its effectiveness would be blunted and learn more about Mikhail.

In its mode of action, rapamycin acts by suppressing geroconversion which in actual sense is the cellular basis for the aging process in all organisms. Therefore, its administration responds by countering specific aging agents in all organisms, for example, plasma sodium, the concentration of chloride and calcium.

Posted on

Oncotarget: A Leading Peer To Peer Review Journal on Cancer

Everyone dreads on the mention of cancer. It is thought to be among the top killer diseases world over. According to a recent statistic, there will be an upwards of 16,688,780 of estimated cancer detection cases, in 2017, not to mention the worrying number of deaths. Sensitization is where we should start if we want to mitigate these cases. Talking about awareness and trying to find out new ways to curb the epidemic, no known review journal has done better regarding demystification than Oncotarget.

This is a worldwide peer review journal that focuses on the pathological basis of all cancers. Oncotarget was started in 2010, published by Impact Journal and is a member and conforms to the set Principles of the Committee on Publication Ethics, COPE. COPE is a body made up of top editors and publishers and is charged with ensuring that all publications in the peer review journals adhere to all publication ethics. On the other hand, COPE advises editors on how to handle cases of research and publication flaws and misconducts. Check the journal at SCImago Journal & Country Rank.

In the recent past, this journal has gotten famous, due to its punctual, insightful, and constructive reviews that help its researchers to deepen their research on this deadly disease. It helps to make known potential targets, treatment procedures, and protocols and also helps cancer patients to manage their condition. Readers learn about the newest therapies available today, evidence to show and support the fact that these treatments work, and also helps them better accept their condition, thus living a quality life. On the other hand, medical practitioners also benefit immensely.

Other than Oncology, this journal also welcomes papers on various topics such as Neuroscience, Cell Biology, Endocrinology, Cardiology, Metabolism, and Pharmacology amongst many other disciplines.

This journal has a popular editorial bar consisting of the former editor in chief of Cancer Research, Board Carlo M. Croce, and Andrew Schally, who is also a Nobel Prize winner. Schally has had his ten papers published on Oncortaget. This journal boasts of having, since its inception, 4 of its members, Bert Vogelstein, Michael N. Hall, Alexander Varshavsky, and Stephen J. Elledge winning the Breakthrough Prize. This prize is considered the highest price ever. Oncotarget, which is published by Impact Journals